Cardiology · Non-Obstructive Coronary Artery Disease

Non-Obstructive Coronary Artery Disease (NOCAD / INOCA / MINOCA): A Patient Guide

At a Glance

Non-obstructive coronary artery disease means the major heart arteries have no blockage of 50% or more, but symptoms or a heart attack can still occur. Small-vessel dysfunction and artery spasm require targeted testing and treatment based on the underlying mechanism.

Receiving a “clear” or “normal” report after a heart angiogram should be a moment of relief, yet for many patients, it is the beginning of a frustrating search for answers. If you are experiencing chest pain, shortness of breath, or have even suffered a heart attack despite having no major blockages, you are likely dealing with a form of Non-Obstructive Coronary Artery Disease (NOCAD). NOCAD generally describes non-obstructive coronary anatomy, which may include plaque without ischemia; it confirms that your large “epicardial” arteries do not have a 50% or greater blockage, but it does not itself establish that your heart is currently failing to receive oxygen ^[1].

If you remember only three things:

A non-obstructive angiogram does not equal a normal symptom experience; your pain is valid.
The exact diagnosis depends on evidence of ischemia or infarction and finding the true cause.
New or changing chest pain still requires urgent assessment, regardless of a clear past angiogram.

This condition is not a single disease but a broad category that includes distinct clinical presentations. ANOCA refers to angina with non-obstructive arteries. INOCA (Ischemia with Non-Obstructive Coronary Arteries) describes chronic chest pain where objective ischemia has been demonstrated, while MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries) is a formally defined working diagnosis for a heart attack that requires an etiologic workup without a visible blockage ^[2]^[3]. For years, these conditions were mistakenly dismissed as benign or “low risk.” Modern research has debunked this myth, showing that patients with non-obstructive disease face a real risk of future heart events and often experience a significant impact on their daily quality of life ^[4]^[5].

The core of the problem is often “functional” rather than “structural.” While traditional heart disease focuses on the “big pipes” of the heart, NOCAD often involves the “micro-plumbing”—the vast network of tiny vessels that are too small to see on a standard angiogram ^[6]. This is known as Coronary Microvascular Dysfunction (CMD). In other cases, the issue is vasospasm, where the heart’s arteries suddenly and inappropriately “cramp” or constrict, temporarily cutting off blood flow ^[7]. Because these issues involve how the vessels behave rather than how they look, they require specialized testing to be properly identified ^[8].

Effective management depends entirely on identifying your specific “endotype”—the precise mechanism causing your heart’s distress. A “one-size-fits-all” approach to heart medication often fails in NOCAD because a drug that helps with vessel spasms may not be the best choice for microvascular resistance ^[9]^[10]. By moving beyond the anatomical “plumbing” view of the heart and focusing on how your unique blood vessels function, you and your care team can develop a targeted treatment plan that validates your symptoms and protects your long-term heart health ^[11]^[12].

In this guide

6 chapters

Understanding Your Diagnosis: NOCAD, INOCA, and MINOCA

Learn what non-obstructive coronary artery disease—NOCAD, INOCA, and MINOCA—means after a clear angiogram, including follow-up tests and heart-event risk.

The Biology: Microvascular Disease and Vasospasm

Learn how nonobstructive coronary artery disease can involve small-vessel dysfunction, endothelial problems, vasospasm, menopause, and different endotypes.

Getting the Right Diagnosis: Invasive Testing and Imaging

Learn how nonobstructive coronary artery disease is diagnosed with coronary function testing, CFR, IMR, acetylcholine provocation, and cardiac MRI for MINOCA.

Treatment Strategies for Nonobstructive Heart Disease

Learn how nonobstructive coronary artery disease is treated, including lifestyle changes, statins, anti-anginal medicines, and care for INOCA or MINOCA.

Living with NOCAD: Managing Symptoms and Knowing the Red Flags

Learn how to live with nonobstructive coronary artery disease (NOCAD), manage chest pain, use cardiac rehabilitation, and recognize emergency warning signs.

Building Your Care Team and Preparing for Appointments

Learn how to build a care team for nonobstructive coronary artery disease, prepare records for a second opinion, and advocate for safe emergency evaluation.

Common questions in this guide

What does a non-obstructive result on a coronary angiogram mean?

It means the large coronary arteries do not have a blockage of 50% or more. It does not necessarily mean the arteries are completely normal or that blood flow is adequate, because plaque, small-vessel dysfunction, or artery spasm may still cause symptoms.

Can I have real angina if my angiogram looks clear?

Yes. Chest pain and shortness of breath can result from coronary microvascular dysfunction, in which tiny vessels do not work normally, or vasospasm, in which an artery temporarily tightens. These problems may not be visible on a standard angiogram, so symptoms should not be dismissed.

What is the difference between ANOCA, INOCA, and MINOCA?

ANOCA means angina with non-obstructive coronary arteries. INOCA means objective evidence of ischemia despite no major blockage, while MINOCA is a working diagnosis for a heart attack without an obstructive blockage and requires testing to find the cause.

How do doctors find out whether NOCAD is caused by small-vessel disease or artery spasm?

The care team may use specialized coronary function testing rather than relying only on the angiogram. Invasive testing can measure microvascular resistance and flow reserve, helping identify the mechanism and guide treatment.

Why does treatment for non-obstructive coronary disease depend on the endotype?

An endotype is the specific mechanism causing the problem, such as microvascular dysfunction or vasospasm. Medication that helps prevent artery spasm may not be the best choice for high resistance in the small vessels, so treatment is matched to the identified mechanism.

Does MINOCA require more tests after a heart attack?

Yes. MINOCA is a working diagnosis, not a final explanation, so the cause needs to be investigated. Cardiac MRI may help look for conditions that can mimic a heart attack, including myocarditis or Takotsubo syndrome.

Is non-obstructive coronary artery disease harmless?

No. Even without a major blockage, people with these conditions can have persistent symptoms, impaired quality of life, and a real risk of future heart events. New or changing chest pain needs urgent medical assessment, even if an earlier angiogram was called clear.

Curated prompts to bring to your next appointment.

1.Based on my angiogram, do I have mild plaque (NOCAD) or truly normal arteries?
2.Since my arteries are non-obstructive, how will we determine if my pain is caused by microvascular disease or vasospasm?
3.What specific endotype of heart disease am I being treated for, and how does my medication reflect that?
4.If I have had a heart attack (MINOCA), have we ruled out 'mimics' like myocarditis or Takotsubo syndrome with a Cardiac MRI?
5.Should we perform invasive coronary function testing to measure my microvascular resistance and flow reserve?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (12)

1
Coronary functional assessment in non-obstructive coronary artery disease: Present situation and future direction.
Zhai C, Fan H, Zhu Y, et al.
Frontiers in cardiovascular medicine 2022; (9()):934279 doi:10.3389/fcvm.2022.934279.
PMID: 36082113
2
Diagnostic pathways in myocardial infarction with non-obstructive coronary artery disease (MINOCA).
Occhipinti G, Bucciarelli-Ducci C, Capodanno D
European heart journal. Acute cardiovascular care 2021; (10(7)):813-822 doi:10.1093/ehjacc/zuab049.
PMID: 34179954
3
Phenotype-based management of coronary microvascular dysfunction.
Ang DTY, Berry C, Kaski JC
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2022; (29(6)):3332-3340 doi:10.1007/s12350-022-03000-w.
PMID: 35672569
4
An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.
Kunadian V, Chieffo A, Camici PG, et al.
European heart journal 2020; (41(37)):3504-3520 doi:10.1093/eurheartj/ehaa503.
PMID: 32626906
5
Clinical Relevance of Ischemia with Nonobstructive Coronary Arteries According to Coronary Microvascular Dysfunction.
Lee SH, Shin D, Lee JM, et al.
Journal of the American Heart Association 2022; (11(9)):e025171 doi:10.1161/JAHA.121.025171.
PMID: 35475358
6
Exploring coronary microvascular dysfunction from functional impairment and structural damage.
Wen W, Zhang Y, Jia G, Chi Y
Frontiers in cardiovascular medicine 2025; (12()):1600947 doi:10.3389/fcvm.2025.1600947.
PMID: 41696543
7
Endothelium in Coronary Macrovascular and Microvascular Diseases.
Godo S, Takahashi J, Yasuda S, Shimokawa H
Journal of cardiovascular pharmacology 2021; (78(Suppl 6)):S19-S29 doi:10.1097/FJC.0000000000001089.
PMID: 34840261
8
Diagnostic approach in patients with angina and no obstructive coronary artery disease: emphasising the role of the coronary function test.
Konst RE, Damman P, Pellegrini D, et al.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2021; (29(3)):121-128 doi:10.1007/s12471-020-01532-9.
PMID: 33415605
9
Functional coronary vascular disease: endotype-based classification, diagnosis, and targeted management.
El Khatib O, Al Azzoni A, Shantouf R, Atallah B
Frontiers in cardiovascular medicine 2026; (13()):1811419 doi:10.3389/fcvm.2026.1811419.
PMID: 42548607
10
Non-invasive and invasive diagnostic modalities for the assessment of coronary vasomotor dysfunction in ANOCA patients.
Bijloo I, Woudstra J, Aribas E, et al.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2026; (22(5)):e283-e291 doi:10.4244/EIJ-D-25-00250.
PMID: 41770271
11
The role of a comprehensive two-step diagnostic evaluation to unravel the pathophysiology of MINOCA: A review.
Pelliccia F, Pepine CJ, Berry C, Camici PG
International journal of cardiology 2021; (336()):1-7 doi:10.1016/j.ijcard.2021.05.045.
PMID: 34087335
12
Invasive Functional Coronary Assessment in Myocardial Ischemia with Non-Obstructive Coronary Arteries: from Pathophysiological Mechanisms to Clinical Implications.
Rinaldi R, Salzillo C, Caffè A, Montone RA
Reviews in cardiovascular medicine 2022; (23(11)):371 doi:10.31083/j.rcm2311371.
PMID: 39076191

This page is for informational purposes only and does not constitute medical advice or diagnose the cause of your chest pain. A prior non-obstructive angiogram does not make new or changing chest pain safe to ignore; seek urgent medical care and discuss testing and treatment with your cardiology team.

Get notified when new evidence is published on nonobstructive coronary artery disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents